Kimie Sai

Kimie Sai

Auto-generated profile, based on publicly available information

Kimie Sai

Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 July 2010 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
KSKimie Sai
Kimie Sai
YSYoshiro Saito
Yoshiro Saito
NTNaoko Tatewaki
Naoko Tatewaki
MHMasakiyo Hosokawa
Masakiyo Hosokawa
NKNahoko Kaniwa
Nahoko Kaniwa
HOHaruhiro Okuda
Haruhiro Okuda
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Association of UDP-glucuronosyltransferase 1A1 (UGT1A1) genetic polymorphisms *6 and *28 with reduced clearance of SN-38 and severe neutropenia in irinotecan therapy was demonstrated in Japanese cancer patients. • The detailed gene structure of CES1 has been characterized. • Possible functional SNPs in the promoter region have been reported. WHAT THIS STUDY ADDS • Association of functional CES1 gene number with AUC ratio [(SN-38 + SN-38G)/irinotecan], an in vivo index of CES activity, was observed in patients with irinotecan monotherapy. • No significant effects of major CES1 SNPs on irinotecan PK were detected. AIMS Human carboxylesterase 1 (CES1) hydrolyzes irinotecan to produce an active metabolite SN-38 in the liver. The human CES1 gene family consists of two functional genes, CES1A1 (1A1) and CES1A2 (1A2), which are located tail-to-tail on chromosome 16q13-q22.1 (CES1A2-1A1). The pseudogene CES1A3 (1A3) and a chimeric CES1A1 variant (var1A1) are also found as polymorphic isoforms of 1A2 and 1A1, respectively. In this study, roles of CES1 genotypes and major SNPs in irinotecan pharmacokinetics were investigated in Japanese cancer patients. METHODS CES1A diplotypes [combinations of haplotypes A (1A3-1A1), B (1A2-1A1), C (1A3-var1A1) and D (1A2-var1A1)] and the major SNPs (−75T>G and −30G>A in 1A1, and −816A>C in 1A2 and 1A3) were determined in 177 Japanese cancer patients. Associations of CES1 genotypes, number of functional CES1 genes (1A1, 1A2 and var1A1) and major SNPs, with the AUC ratio of (SN-38 + SN-38G)/irinotecan, a parameter of in vivo CES activity, were analyzed for 58 patients treated with irinotecan monotherapy. RESULTS The median AUC ratio of patients having three or four functional CES1 genes (diplotypes A/B, A/D or B/C, C/D, B/B and B/D; n= 35) was 1.24-fold of that in patients with two functional CES1 genes (diplotypes A/A, A/C and C/C; n= 23) [median (25th–75th percentiles): 0.31 (0.25–0.38) vs. 0.25 (0.20–0.32), P= 0.0134]. No significant effects of var1A1 and the major SNPs examined were observed. CONCLUSION This study suggests a gene-dose effect of functional CES1A genes on SN-38 formation in irinotecan-treated Japanese cancer patients.

22 September 2009 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KSKimie Sai
Kimie Sai
YSYoshiro Saito
Yoshiro Saito
KMKeiko Maekawa
Keiko Maekawa
SKSu-Ryang Kim
Su-Ryang Kim
NKNahoko Kaniwa
Nahoko Kaniwa
HMHironobu Minami
Hironobu Minami

1 August 1998 in Cancer Letters
Verified
Journal Article
Closed access
KSKimie Sai
Kimie Sai
BUBrad L. Upham
Brad L. Upham
KKKyung-Sun Kang
Kyung-Sun Kang
RHRyuichi Hasegawa
Ryuichi Hasegawa
TITohru Inoue
Tohru Inoue
JTJames E Trosko
James E Trosko

1 November 2001 in Cancer Letters
Verified
Journal Article
Closed access
KSKimie Sai
Kimie Sai
KKKyung-Sun Kang
Kyung-Sun Kang
AHAkihiko Hirose
Akihiko Hirose
RHRyuichi Hasegawa
Ryuichi Hasegawa
JTJames E. Trosko
James E. Trosko
TITohru Inoue
Tohru Inoue

18 March 2008 in Cancer Letters
Verified
Journal Article
Closed access
KSKimie Sai
Kimie Sai
YSYoshiro Saito
Yoshiro Saito
HSHiromi Sakamoto
Hiromi Sakamoto
KSKuniaki Shirao
Kuniaki Shirao
KKKoichi Kurose
Koichi Kurose
TYTeruhiko Yoshida
Teruhiko Yoshida